Uncategorized Cantor Fitzgerald Reaffirms Overweight Rating for Celldex Therapeutics (NASDAQ:CLDX) otakuyassine3@gmail.com Jan 4, 2025 Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “overweight” rating restated by stock...